|
|
|
| Clinical Efficacy of Zopiclone in the Treatment of Schizophrenia Complicated with Sleep Disorder and its Effect on the Level of Related Nerve Factors |
| LI Ying, AN Guo-song |
| the Second Veteran Hospital of Shanxi Province, Huayin 714200,China |
|
|
|
|
Abstract 【Objective】To explore the clinical effect and mechanism of zopiclone in the treatment of schizophrenia with sleep disorders. 【Methods】The clinical data of 90 patients with schizophrenia complicated with sleep disorder treated in our hospital from February 2019 to February 2020 were retrospectively analyzed. According to different treatment methods, they were divided into control group and observation group, with 45 cases in each group. The control group was given oral aripiprazole + alprazolam, and the observation group was given oral aripiprazole + zopiclone. The clinical efficacy, sleep quality(PSQI), serum serotonin(5-HT) and nuclear transcription factor were compared between the two groups before and after treatment-κB(NF-κB). The adverse reactions of the two groups were observed and recorded. 【Results】After one week of treatment, the PSQI score of the observation group was lower than that of the control group(P<0.05); There was no significant difference in PSQI scores between the two groups before treatment, 2 weeks and 3 weeks of treatment(P>0.05). The effective rate of the observation group was 75.56%(34/45), which was significantly higher than 55.56%(25/45) of the control group(χ2 =3.986,P=0.046＜0.05). After treatment, serum NF-κB , the level of was lower than that before treatment, and the level of 5-HT was higher than that before treatment, and there was significant difference between the observation group and the control group(P<0.05). The incidence of adverse reactions in the observation group was 24.44%(11/45), which was lower than 44.44%(20/45) in the control group(P<0.05).【Conclusion】Zopiclone can better improve the sleep quality of schizophrenic patients with sleep disorders, and the incidence of adverse reactions is less. It may be related to the regulation of serum 5-HT and NF-κB by zopiclonelevel.
|
|
Received: 10 October 2020
|
|
|
|
|
|
[1] 杨丽娟, 李占江, 曾妍妍,等. 精神分裂症共病失眠患者睡眠认知特征及相关因素研究[J].中华行为医学与脑科学杂志, 2018,26(5):400-404.
[2] 张颖. 认知行为疗法联合右佐匹克隆片治疗ICU转出患者睡眠障碍的疗效观察[J].浙江医学, 2018, 40(7):54-58.
[3] 谭丽阳. 右佐匹克隆对老年痴呆患者睡眠障碍状态改善的临床分析[J].中国医师进修杂志, 2020, 43(2):171-174.
[4] 贾谊诚.对《中国精神障碍分类与诊断标准,第3版》(CCMD-3)的讨论(一)几点意见,以供商榷[J].临床精神医学杂志,2002,12(1):35-39.
[5] 张苹. 精神分裂症伴迟发性运动障碍患者基因甲基化谱的初步构建[J].中华精神科杂志, 2018,63(1):13-19.
[6] 王素娟, 毛赛锦, 李金亮. 探讨三种非典型抗精神病药物对精神分裂症患者血清性激素水平的影响[J].重庆医学, 2017,45(46):128.
[7] 刘科峰, 彭忠禄, 罗神敏. 佐匹克隆对Ⅰ级高血压合并睡眠障碍患者血压的影响[J].中国动脉硬化杂志, 2017,24(25):918.
[8] STANISLAV N, GIANNA W M, JULIE H, et al. AMPK signaling linked to the schizophrenia-associated 1q21.1 deletion is required for neuronal and sleep maintenance[J].PLoS Genet,2018,14(12):1007-1010.
[9] 关凤华. 黄连温胆汤对血压合并睡眠障碍患者临床症状及血清5-HT、P物质水平的影响[J].中华中医药学刊, 2018, 36(4):923-926.
[10] 陶瑞. 佐匹克隆联合黛力新对卒中后抑郁患者细胞因子及神经递质的影响[J].海南医学院学报, 2018, 24(4):476-479.
[11] 黄宇, 贺王伟, 黄峥嵘. 佐匹克隆与盐酸曲唑酮治疗睡眠障碍的临床疗效观察[J].安徽医药, 2018, 22(6):1142-1144.
|
|
|
|
2021, Vol. 38 
